Preclinical Studies and Clinical Correlation of the Effect of Alkylating Dose

Cancer Research

Volumn 48, Issue 22, 1988, Pages 6417-6423

  Frei, Emil ^a   Teicher, Beverly A ^a   Holden, Sylvia A ^a   Cathcart, Kathleen N S ^a   Wang, Yenyun ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; CARMUSTINE; CHLORMETHINE; CISPLATIN; MELPHALAN; MITOMYCIN C; THIOTEPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CELL CULTURE; DOSE RESPONSE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ALKYLATING AGENTS; ANIMAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARMUSTINE; CELL SURVIVAL; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMAN; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0023798680     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Colvin, M. The alkylating agents. In: B. Chabner (ed.), Pharmacologie Principles of Cancer Treatment, pp. 276-306. Philadelphia: Saunders, 1982.
2. Frei, E., III, and Canellos, G. P. Dose, a critical factor in cancer chemotherapy. Am. J. Med., 69: 585-594, 1980.
3. Frei, E., III. Curative cancer chemotherapy. Cancer Res., 45: 6523-6537, 1985.
4. Peters, W. P., Eder, J. P., Henner, W. D. Schryber, S., Wilmore, D., Finberg, R., Schoenfeld. D., Bast, R., Gargone, B., Animan, K., Anderson, J., Anderson, K., Kriskall. M. S., Schnipper, L., and Frei, E., III. High dose combination alkylating agents with autologous bone marrow support: a Phase I trial. J. Clin. Oncol., 4: 646-654, 1986.
5. Thomas, E. D. The role of marrow transplantation in the eradication of malignant disease. Cancer (Phila.). 49: 1963-1969, 1982.
6. Phillips, G. L., Fay, J. W., Herzig. G. P., Herzig, R. H., Weiner, R. S., Wolff, S. N., Lazarus, H. M., Karanes, C., Ross, W. E., and Kramer, B. S. Intensive l, 3-bis(2-chloroethyl)-l-nitrosourea(BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A Phase l-II study. Cancer (Phila.), 52: 1792-1802, 1983.
7. Eder, J. P., Amman, K., Peters, W., Henner, W. D., Elias, A., Shea, T. C., Schryber, S., Andersen, J., Corne, S., Schnipper, L., and Frei, E., III. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J. Clin. Oncol., 4: 1592-1597, 1986.
8. Schabel, F. M., Jr., Trader, M. W., Laster, W. R., Jr., Wheeler, G. P., and Witt, M. H. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot. Chemother., 23: 200-215, 1978.
9. Frei, E., III, Cucchi, C. A., Rosowsky, A., Tantravahi, R., Bernal, S., Ervin, T. J., Ruprecht, R. M., and Haseltine, W. A. Alkylating agent resistance: in vitro studies with human cell lines. Proc. Natl. Acad. Sci. USA, 82: 2158-2162, 1985.
10. Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to ff's-diamminedichloroplatinum(II). Cancer Res., 47: 388-393, 1987.
11. Tannock, I. F. Experimental chemotherapy and concepts related to the cell cycle. Int. J. Radiat.Biol. Relat. Stud. Phys. Chem. Med. 49: 335-355, 1986.
12. Pratt, W. B., and Ruddon, R. W. The Anticancer Drugs, pp. 20-42. New York: Oxford University Press, 1979.
13. Teicher, B. A., Lazo, J. S., and Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41: 73-81, 1981.
14. Teicher, B. A., Holden, S. A., and Rose, C. M. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J. Natl. Cancer IHM., 75: 1129-1133, 1985.
15. lannaccone, P. M., Weinberg, W. C., and Deamant, F. D. On the clonal origin of tumors: a review of experimental models. Int. J. Cancer, 39: 778-784, 1987.
16. Kendal, W. S., and Frost, P. Metastatic potential and spontaneous mutation rates: studies with two murine cell lines and their recently induced metastatic variants. Cancer Res., 46: 6131-6135, 1986.
17. Goldie, J. H., and Coldman, A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res., 44; 3643-3653, 1984.
18. Wittes, R. E., and Goldin, A. Unresolved issues in combination chemotherapy. Cancer Treat. Rep., 70: 105-125, 1986.
19. Teicher, B. A., and Frei, E., III. Development of alkylating agent resistant human tumor cell lines. Cancer Chemother. Pharmacol., 21: 292-298, 1988.
20. Dorr, R. T., and Fritz, W. L. Cancer Chemotherapy Handbook, p. 297. New York: Elsevier Press, 1980.
21. Summerhayes, I. C., Lampidis, T. J., Bernai, S. D., Nadakavukaren, J. J., Nadakavukaren, K. K., Shepard, E. L., and Chen, L. B. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc. Natl. Acad. Sci. USA, 79: 5292-5296, 1982.
22. Lampidis, T. J., Bernai, S. D., Summerhayes, I. C., and Chen, L. B. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res., 43: 716-720, 1983.
23. Rice, L., Urano, M., and Suit, H. D. The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. Br. J. Cancer, 41: 240-245, 1980.
24. Teicher, B. A., and Rose, C. M. Perfluorochemical emulsions can increase tumor radiosensitivity. Science (Wash. DC), 223: 934-936, 1984.
25. Rockwell, S., Kallman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue culture adaption. J. Natl. Cancer Inst., 49: 735-749, 1972.
26. Rockwell, S., and Kallman, R. F. Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat.Res., 53: 281-294, 1973.
27. Rockwell, S. In vivo-in vitro tumor systems: new models for studying the response of tumors in therapy. Lab. Anim. Sci., 27: 831-851, 1977.
28. Rockwell, S. Cytotoxic and radiosensitizing effects of hypoxic cell sensitizers on EMT6 mouse mammary tumor cells in vivo and in vitro. Br. J. Cancer, 37: 212-215, 1978.
29. Teicher, B. A., Holden, S. A., and Jacobs, J. L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res., 47: 513-518, 1987.
30. Litchfield, J. T., and Wilcoxon, F. A. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96: 99, 1949.
31. Tallarida, R. J., and Murray, R. B. Manual of Pharmacologie Calculations with Computer Programs. New York: Springer-Verlag, 1981.
32. Teicher, B. A., Lee, J. B., Animan, K., and Frei, E., III. Metabolic activation of thiotepa. Proc. Am. Assoc. Cancer Res., 29: 487, 1988.
33. Carter, S. K., and Livingston, R. B. Drugs available to treat cancer. In: S. K. Carter, E. Glatstein, and R. B. Livingston (eds.), Principles of Cancer Treatment, pp. 111-146. New York: McGraw-Hill, 1982.
34. Alberts, D. S., and Chen, H-S. G. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Cloning of Human Tumor Stem Cells, pp. 351-359. New York: Alan R. Liss, 1980.
35. Struck, R. F., Alberts, D. S., Home, K., Phillips, J. G., Peng, Y.-M., and Roe, D. J. Plasmapharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized crossover trial. Cancer Res., 47: 2723-2726, 1987.
36. Alberts, D. S., Chang, S. Y., Chen, H-S. G., Larcon, B. J., and Evans, T. L. Comparative pharmacokinetics of chlorambucil and melphalan in man. In: G. Mathe and F. M. Muggia (eds.). Recent Results in Cancer Research, Vol.74, pp. 124-131. New York: Springer-Verlag, 1980.
37. Colvin, M. The alkylating agents. In: B. Chabner (ed.).Pharmacologie Principles of Cancer Treatment, pp. 209-293. Philadelphia: Saunders, 1982.
38. Reed, D. J. 2-Chloroethylnitrosoureas. In: G. Powis and R. A. Prough (eds.), Metabolism and Action of Anti-Cancer Drugs, pp. 1-280. New York: Taylor & Francis, 1987.
39. Frei.E., III, Rosowsky, A., Wright, J. E., Cucchi, C. A., Lippke, J. A., Ervin, T. J., Jolivet, J., and Haseltine, W. A. Development of methotrexate resistance in a human squamous cellcarcinoma of the head and neck in culture. Proc. Natl. Acad. Sci. USA, 81: 2873, 1977.
40. Schimke, R. T., Beverly, S., Brown, P., Cassin, R., Federspiel, N., Gasser, C., Hill, A., Johnston, R., Mariani, B., Mosse, E., Rath, H., Smouse, D., and Tlsty, T. Gene amplification and drug resistance in cultured animal cells. Cancer Treat. Rev., 11: 9, 1984.
41. Harker, W.G., and Sikic, B.I. Multidrug (pleiotropic) resistance in doxo-rubicin-selected variants of the human srcoma cell line MES-SA. Cancer Res., 45: 4091-4098, 1985.
42. Twentyman, P. R., Fox, N. W., Wright, K. A., and Bleehan, N. M. Derivation and preliminary characterization of Adriamycin resistant lines of human lung ancer cells, Br. J. Cancer, 53: 529, 1986.
43. Goldie, J. H., and Goldman, A. J. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Invest., 3: 553, 1985.
44. Schimke, R. T. Gene amplification in cultured animal cells. Cell, 37: 705, 1984.
45. Vrignaud, P., Londos-Gagliarfi, D., and Robert, J. Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. Oncology, 43: 60, 1986.